The present invention provides a pharmaceutical composition for
suppression of the expression of ATP citrate lyase, which contains a
compound that suppresses the expression of ATP citrate lyase by the in
vivo administration. The compounds suppress the expression of ATP citrate
lyase by the in vivo administration include insulin secretagogues such as
nateglinide. This pharmaceutical composition is effective in preventing,
improving and treating metabolic syndrome, in particular, liver disorders
related to abnormal lipid metabolism such as fatty liver and NASH.
